Get Your Personalized Supplement StackSupplement Stack Quiz

Peptizyme Sp

Q: Is Serrapeptase safe for long-term use?

Limited long-term safety data exist; short-term use appears safe. Consult a healthcare provider for extended use.

Q: How quickly does it work?

Benefits such as fatigue reduction may be seen within 1-2 weeks, but individual results can vary.

Q: Can it be taken with other medications?

Caution is advised with blood thinners due to potential interactions. Consult your doctor.

Q: Does it help with joint pain?

Some evidence suggests anti-inflammatory effects, but high-quality data are limited. More research is needed.

Q: Is it effective for respiratory conditions?

It may support respiratory health by reducing mucus and inflammation, but results can vary.

Also known as: Serrapeptase, Serratiopeptidase, Peptizyme SP

Overview

Serrapeptase, also known as serratiopeptidase, is a proteolytic enzyme derived from *Serratia* bacteria. It is marketed as a systemic enzyme supplement to promote the breakdown of proteins and reduce inflammation. Serrapeptase is characterized by its ability to break down non-living tissue, fibrin, and inflammatory mediators. It is available in various formulations, often enteric-coated to protect it from stomach acid. Primary uses include supporting respiratory health, reducing inflammation, improving joint and muscle function, and aiding tissue repair. Research on serrapeptase is considered moderately mature, with several clinical studies exploring its effects, although high-quality, large-scale randomized controlled trials (RCTs) and meta-analyses are still limited. The available evidence includes RCTs and systematic reviews, but many studies have small sample sizes and methodological limitations, impacting the strength of the conclusions.

Benefits

Serrapeptase has shown potential benefits in reducing inflammation and improving symptoms in respiratory and musculoskeletal conditions. A randomized controlled trial (RCT) showed significant resolution of fatigue in post-COVID-19 patients, with 91% in the treatment group fatigue-free by day 14 versus 15% in the placebo group (p < 0.05). Some meta-analyses of proteolytic enzymes, including serrapeptase, suggest benefits in reducing pain and improving function in chronic inflammatory conditions, but the data are heterogeneous and often from small trials. These benefits may be particularly relevant for patients with chronic inflammatory conditions, post-viral fatigue, and respiratory issues. The effect sizes vary; for fatigue post-COVID-19, a large difference was observed, while evidence for other indications is less robust. Benefits in fatigue resolution were observed within 14 days in one RCT.

How it works

Serrapeptase acts by proteolytically degrading inflammatory mediators, fibrin, and dead tissue, potentially reducing inflammation and promoting tissue repair. It is absorbed systemically and may modulate inflammatory pathways, reduce mucus viscosity, and promote clearance of debris in tissues. The primary biological pathways involve targeting fibrin, inflammatory cytokines, and other protein substrates involved in inflammation. Oral serrapeptase is absorbed in an active form, though bioavailability can vary depending on the formulation. This proteolytic action helps in clearing damaged tissues and reducing swelling, contributing to its purported therapeutic effects.

Side effects

Serrapeptase is generally considered safe, with few reported adverse effects in clinical studies. The most common side effect is mild gastrointestinal discomfort, which is occasionally reported. Rare allergic reactions have been observed in some individuals. No significant rare adverse events have been documented in high-quality trials. Potential interactions with anticoagulants exist due to its fibrinolytic activity, so caution is advised when used with blood thinners. It is contraindicated in patients with bleeding disorders or those already on blood thinners. Limited data are available for pregnant or lactating women, so its use is generally avoided in these populations. Overall, the safety profile is favorable, but caution is warranted in specific patient groups.

Dosage

Typical serrapeptase doses range from 10 mg to 60 mg per day, equivalent to 20,000 to 120,000 IU. Clinical studies often use 30,000 to 60,000 IU daily. The maximum safe dose is not well established, but doses above 120,000 IU/day are generally not recommended without medical supervision. It is usually taken on an empty stomach to enhance absorption. Enteric-coated formulations are preferred to protect the enzyme from stomach acid. Food intake can reduce absorption. No specific cofactors are required for its activity. Dosage may vary based on the specific product and the condition being treated, so consulting with a healthcare provider is advisable.

FAQs

Is Serrapeptase safe for long-term use?

Limited long-term safety data exist; short-term use appears safe. Consult a healthcare provider for extended use.

How quickly does it work?

Benefits such as fatigue reduction may be seen within 1-2 weeks, but individual results can vary.

Can it be taken with other medications?

Caution is advised with blood thinners due to potential interactions. Consult your doctor.

Does it help with joint pain?

Some evidence suggests anti-inflammatory effects, but high-quality data are limited. More research is needed.

Is it effective for respiratory conditions?

It may support respiratory health by reducing mucus and inflammation, but results can vary.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC8472462/ – This randomized controlled trial examined the effects of systemic enzymes, including serrapeptase, on post-COVID-19 fatigue. The study found that 91% of patients in the treatment group experienced fatigue resolution by day 14, compared to only 15% in the placebo group (p < 0.05), indicating significant efficacy in reducing fatigue. The study's limitation is its specific focus on fatigue rather than a broader range of post-COVID-19 symptoms.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5530474/ – This systematic review and meta-analysis focused on pancreatic enzyme replacement therapy (PERT) in chronic pancreatitis. While not directly studying serrapeptase, it supports the efficacy of enzyme therapy in digestive conditions, demonstrating improved nutrient absorption and symptom relief. The findings are indirectly relevant to systemic enzymes, suggesting potential benefits in similar digestive-related contexts.
https://www.mdpi.com/2079-9721/12/7/155 – This systematic review assessed the efficacy of serrapeptase based on 11 RCTs with limited sample sizes. The review found some evidence of benefit in inflammatory and pain conditions but noted methodological limitations and heterogeneity among the studies. The authors call for larger, well-designed trials to confirm these preliminary findings and better understand the potential benefits of serrapeptase.
https://www.e-lactancia.org/media/papers/SerratiopeptidasaEficcia-IntJouSurg2013.pdf – This paper discusses the efficacy of Serratiopeptidase. It is an older paper, but it provides some evidence of benefit in inflammatory and pain conditions. It is important to note that the study has methodological limitations.
https://specialtyenzymes.com/products/systemic-enzymes/peptizyme-sp/ – This is a product page for Peptizyme SP. It provides information on the product's ingredients, benefits, and dosage. It is not a peer-reviewed research article, but it can be a useful source of information.